Skip to main content
Erschienen in: Supportive Care in Cancer 3/2009

01.03.2009 | Original Article

Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)

verfasst von: Richard J. Gralla, Martin J. Edelman, Frank C. Detterbeck, Thierry M. Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, Guangbin Peng, Matthew J. Monberg, Coleman K. Obasaju, Mark A. Socinski

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available—such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment.

Materials and methods

The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months.

Results

Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84% had an ECOG performance status of 0, 93% had a complete resection, and 67% (95% CI = 52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33%). These patients experienced a mean worsening of 66% in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining.

Conclusions

Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.
Literatur
1.
Zurück zum Zitat Ahrendt SA, Yang SC, Wu L et al (2002) Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg 123(3):466–473 discussion 473–464 doi:10.1067/mtc.2002.120343 PubMedCrossRef Ahrendt SA, Yang SC, Wu L et al (2002) Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg 123(3):466–473 discussion 473–464 doi:10.​1067/​mtc.​2002.​120343 PubMedCrossRef
2.
Zurück zum Zitat Betticher DC, Hsu Schmitz SF, Totsch M et al (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94(8):1099–1106 doi:10.1038/sj.bjc.6603075 PubMedCrossRef Betticher DC, Hsu Schmitz SF, Totsch M et al (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94(8):1099–1106 doi:10.​1038/​sj.​bjc.​6603075 PubMedCrossRef
3.
Zurück zum Zitat Bezjak A, Lee C, Ding K et al (2007) Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): final analysis of JBR.10 randomized trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25:7585. (abstract) Bezjak A, Lee C, Ding K et al (2007) Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): final analysis of JBR.10 randomized trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25:7585. (abstract)
4.
Zurück zum Zitat Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756PubMed Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756PubMed
5.
Zurück zum Zitat Choong NW, Vokes EE (2005) Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 7(Suppl 3):S98–S104PubMedCrossRef Choong NW, Vokes EE (2005) Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 7(Suppl 3):S98–S104PubMedCrossRef
6.
Zurück zum Zitat D’Cunha J, Corfits AL, Herndon JE 2nd et al (2002) Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer—preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg 123(3):484–491 discussion 491 doi:10.1067/mtc.2002.119883 PubMedCrossRef D’Cunha J, Corfits AL, Herndon JE 2nd et al (2002) Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer—preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg 123(3):484–491 discussion 491 doi:10.​1067/​mtc.​2002.​119883 PubMedCrossRef
7.
Zurück zum Zitat De Marinis F, Pereira J, Fossella F et al (2008) Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small-cell lung cancer. J Thorac Oncol 3:30–36PubMedCrossRef De Marinis F, Pereira J, Fossella F et al (2008) Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small-cell lung cancer. J Thorac Oncol 3:30–36PubMedCrossRef
8.
Zurück zum Zitat Depierre A, Milleron B, Moro-Sibilot D et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20(1):247–253 doi:10.1200/JCO.20.1.247 PubMedCrossRef Depierre A, Milleron B, Moro-Sibilot D et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20(1):247–253 doi:10.​1200/​JCO.​20.​1.​247 PubMedCrossRef
12.
Zurück zum Zitat Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77(4):371–383PubMedCrossRef Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77(4):371–383PubMedCrossRef
14.
Zurück zum Zitat Hollen PJ, Gralla RJ, Kris MG et al (1994) Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73(8):2087–2098 doi:10.1002/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-XPubMedCrossRef Hollen PJ, Gralla RJ, Kris MG et al (1994) Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73(8):2087–2098 doi:10.1002/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-XPubMedCrossRef
15.
Zurück zum Zitat Hollen PJ, Gralla RJ, Kris MG, Cox C (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2(4):213–222 doi:10.1007/BF00365725 PubMedCrossRef Hollen PJ, Gralla RJ, Kris MG, Cox C (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2(4):213–222 doi:10.​1007/​BF00365725 PubMedCrossRef
16.
Zurück zum Zitat Hopwood P, Nankivell M, Pugh C, Gilligan D, Nicholson M, Stephens R (2007) Impact of pre-operative chemotherapy on the quality of life (QL) of patients with resectable non-small cell lung cancer (NSCLC): experience from the MRC LU22/NVALT/EORTC 08012 multicentre randomised trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25:9020 (abstract) Hopwood P, Nankivell M, Pugh C, Gilligan D, Nicholson M, Stephens R (2007) Impact of pre-operative chemotherapy on the quality of life (QL) of patients with resectable non-small cell lung cancer (NSCLC): experience from the MRC LU22/NVALT/EORTC 08012 multicentre randomised trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25:9020 (abstract)
18.
Zurück zum Zitat Manegold C, Bergman B, Chemaissani A et al (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8(6):525–529 doi:10.1023/A:1008207731111 PubMedCrossRef Manegold C, Bergman B, Chemaissani A et al (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8(6):525–529 doi:10.​1023/​A:​1008207731111 PubMedCrossRef
19.
Zurück zum Zitat Martini N, Kris MG, Flehinger BJ et al (1993) Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55(6):1365–1373 discussion 1373–1364PubMedCrossRef Martini N, Kris MG, Flehinger BJ et al (1993) Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55(6):1365–1373 discussion 1373–1364PubMedCrossRef
21.
Zurück zum Zitat Pantel K, Izbicki JR, Angstwurm M et al (1993) Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 53(5):1027–1031PubMed Pantel K, Izbicki JR, Angstwurm M et al (1993) Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 53(5):1027–1031PubMed
22.
23.
25.
Zurück zum Zitat Rivera M, Detterbeck FC, Socinski MA et al (2005) Neoadjuvant chemotherapy with gemcitabine-containing regimens in stage I-II non-small cell lung cancer (NSCLC): initial results of pre-operative pulmonary function testing (PFTs) in the GINEST project. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23:7227 (abstract) Rivera M, Detterbeck FC, Socinski MA et al (2005) Neoadjuvant chemotherapy with gemcitabine-containing regimens in stage I-II non-small cell lung cancer (NSCLC): initial results of pre-operative pulmonary function testing (PFTs) in the GINEST project. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23:7227 (abstract)
27.
Zurück zum Zitat Roth JA, Atkinson EN, Fossella F et al (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21(1):1–6 doi:10.1016/S0169-5002(98)00046-4 PubMedCrossRef Roth JA, Atkinson EN, Fossella F et al (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21(1):1–6 doi:10.​1016/​S0169-5002(98)00046-4 PubMedCrossRef
29.
Zurück zum Zitat Treat J, Belani C, Edelman M et al (2005) A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). Proc Am Soc Clin Oncol 23:7025 (abstract) Treat J, Belani C, Edelman M et al (2005) A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). Proc Am Soc Clin Oncol 23:7025 (abstract)
30.
Zurück zum Zitat van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117(2):374–379 doi:10.1378/chest.117.2.374 PubMedCrossRef van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117(2):374–379 doi:10.​1378/​chest.​117.​2.​374 PubMedCrossRef
Metadaten
Titel
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
verfasst von
Richard J. Gralla
Martin J. Edelman
Frank C. Detterbeck
Thierry M. Jahan
David M. Loesch
Steven A. Limentani
Ramaswamy Govindan
Guangbin Peng
Matthew J. Monberg
Coleman K. Obasaju
Mark A. Socinski
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0489-y

Weitere Artikel der Ausgabe 3/2009

Supportive Care in Cancer 3/2009 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.